Eric Coronato, DO
Urology · Spartanburg, SCNPI 1740304419
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,242 of the $7,299 with a category attached, or 85.5%. It is spread thinly across 38 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,531 and has fallen 64.3% since, to $903 in 2025.
Across 253 payments — averaging $28.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$2K
- Procept Biorobotics Corporation$750
- Boston Scientific$598
- Endo Pharmaceuticals Inc.$568
- Medtronic$453
- Johnson & Johnson$397
- plus $3K from 32 others
What the payments were for
- Travel & lodging$1,05614%
- Food & beverage$6,24286%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 17 | $1,613 |
| Procept Biorobotics Corporation | 6 | $750 |
| Boston Scientific | 22 | $598 |
| Endo Pharmaceuticals Inc. | 37 | $568 |
| Medtronic(2 entities) | 10 | $453 |
| Johnson & Johnson | 23 | $397 |
| AbbVie(2 entities) | 19 | $349 |
| Neotract Inc. | 4 | $281 |
| Astellas Pharma US Inc | 12 | $215 |
| Antares Pharma, Inc. | 13 | $211 |
| Sumitomo Pharma America, Inc. | 10 | $169 |
| Myriad Genetic Laboratories, Inc. | 9 | $161 |
| Bayer | 7 | $156 |
| Coloplast | 6 | $144 |
| Endo USA, Inc. | 8 | $137 |
| Olympus America Inc. | 4 | $86 |
| C. R. Bard, Inc. & Subsidiaries | 3 | $83 |
| Halozyme Inc | 5 | $82 |
| Ferring Pharmaceuticals Inc. | 4 | $72 |
| Myovant Sciences Inc. | 4 | $71 |
| Tolmar, Inc. | 3 | $70 |
| Olympus Corporation Of The Americas | 1 | $65 |
| Pfizer | 3 | $62 |
| Dendreon Pharmaceuticals LLC | 3 | $60 |
| Merck | 2 | $55 |
| Valencia Technologies Corporation | 1 | $52 |
| KARL Storz Endoscopy-america | 1 | $50 |
| Blue Earth Diagnostics | 2 | $40 |
| Urovant Sciences Inc | 2 | $36 |
| Teleflex LLC | 1 | $33 |
| Progenics Pharmaceuticals, Inc. | 2 | $32 |
| Urogen Pharma, Inc. | 2 | $28 |
| BD | 2 | $28 |
| 180 Medical, Inc. | 1 | $23 |
| Novartis | 1 | $19 |
| Convatec Inc. | 1 | $18 |
| Laborie Medical Technologies Corp. | 1 | $17 |
| Tolmar Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,310
- Bulkamid$1,049
- AQUABEAM SYSTEM$569
- UroLift$252
- AquaBeam Robotic System$131
- INTERSTIM$125
- AMS$107
How this compares
$7,299 in reported general payments places this provider in the 70th percentile of 196 urology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 35 | $493,622 |
| XtandiEnzalutamide | 22 | $300,786 |
| NubeqaDarolutamide | 16 | $205,788 |
| OrgovyxRelugolix | 40 | $111,309 |
| MyrbetriqMirabegron | 41 | $39,222 |
| GemtesaVibegron | 33 | $39,000 |
| Tamsulosin Hcl | 747 | $11,744 |
| Finasteride | 707 | $10,320 |
| Methenamine Hippurate | 74 | $3,462 |
| Solifenacin Succinate | 70 | $2,289 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,172 |
| Estradiol | 26 | $2,014 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 88 | $1,780 |
| NitrofurantoinNitrofurantoin Macrocrystal | 48 | $1,761 |
| Silodosin | 18 | $1,519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $397 | $493,62235 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $215 | $340,00963 claims |
| BayerNubeqa | $156 | $205,78816 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $169 | $150,30973 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 196 urology providers in South Carolina.
Other urology in Spartanburg
- Erin AndersonSpartanburg$9K
- Robert BritaniskySpartanburg$7K
- Robert StrehlowSpartanburg$7K
- Neal ShoreMyrtle Beach$3.2M
- Manish PatelElgin$213K
- Sandip PrasadCharleston$177K
- Benjamin DropkinGreenville$65K
- Ian MarshallCharleston$60K
- Elizabeth BozemanFlorence$57K
- Thomas KeaneCharleston$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.